Radionetics Oncology
Lianna Scott serves as the Senior Manager of Accounting at Radionetics Oncology since February 2024, having previously held the same title at Sapient from June 2022 to January 2024. Lianna's extensive accounting experience includes roles such as Assistant Controller and Senior Manager of Accounting at theSkimm from May 2019 to May 2022, and various accounting positions at EY, including Tax Staff and International Tax Services Intern. Initial experience includes internships at Tishman Speyer, Societe Generale Corporate and Investment Banking, Take-Two Interactive Software, Inc., and Segal Family Office. Lianna holds a Master of Science in Taxation from Fordham Gabelli School of Business and a Bachelor’s Degree in Public Accounting from Fordham University.
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.